ReviewCurrent hematologic malignancy reports2021

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

Tamer Othman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.